^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RAD51C (RAD51 paralog C)

    i
    Apply
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (NCT05941520)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/23/2024
    Primary completion :
    08/23/2027
    Completion :
    09/01/2028
    TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2
    |
    TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    tamoxifen • acolbifene
    Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (NCT05327010)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/14/2022
    Primary completion :
    08/04/2025
    Completion :
    08/04/2025
    KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1
    |
    KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Talzenna (talazoparib) • ZEN-3694
    Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) (NCT05417594)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/24/2022
    Primary completion :
    08/28/2026
    Completion :
    08/28/2026
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D
    |
    HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation
    |
    temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan) • AZD9574
    Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (NCT04266912)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    03/17/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    Bavencio (avelumab) • berzosertib (M6620)
    Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) (NCT05700721)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/02/2023
    Primary completion :
    08/07/2025
    Completion :
    08/07/2027
    PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52
    |
    PD-L1 expression
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Stand Up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068)
    Phase N/A
    M.D. Anderson Cancer Center
    Suspended
    Last update posted :
    02/12/2025
    Initiation :
    04/18/2017
    Primary completion :
    04/18/2026
    Completion :
    04/18/2026
    ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    Men at High Genetic Risk for Prostate Cancer (NCT03805919)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/27/2019
    Primary completion :
    01/01/2029
    Completion :
    01/01/2039
    TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13
    Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (NCT05687110)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/06/2023
    Primary completion :
    08/01/2026
    Completion :
    09/01/2026
    BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    Pembrolizumab, Olaparib, and Temozolomide for People with Glioma (NCT05188508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/14/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors (NCT04126070)
    Phase 2
    Xiao X. Wei, MD
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/11/2020
    Primary completion :
    10/24/2024
    Completion :
    06/30/2025
    PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    Evaluation of a Multimodal Strategy for Early Diagnosis of Men At High Genetic Risk of Prostate Cancer (HRPCa-II) (NCT05333432)
    Phase N/A
    Assistance Publique - Hôpitaux de Paris
    Not yet recruiting
    Last update posted :
    01/28/2025
    Initiation :
    03/01/2025
    Primary completion :
    03/01/2030
    Completion :
    03/01/2030
    TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM) (NCT05222971)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/01/2022
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1
    |
    ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    A Study of Olaparib and Pembrolizumab in People with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer (NCT05203445)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    01/13/2025
    Initiation :
    01/31/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    HER-2 • PGR • BRCA1 • BRCA2 • RAD51C • RAD51D
    |
    HR positive • HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    Niraparib in Tumors Metastatic to the CNS (NCT04992013)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    12/12/2024
    Initiation :
    04/05/2022
    Primary completion :
    12/01/2025
    Completion :
    06/01/2027
    BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3
    |
    HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Zejula (niraparib)
    A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA (NCT05515575)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    11/05/2024
    Initiation :
    08/23/2022
    Primary completion :
    08/01/2026
    Completion :
    08/01/2026
    BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4
    |
    Zejula (niraparib)
    A Study of Pembrolizumab and Olaparib for People with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy (SPORE) (NCT04666740)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    10/14/2024
    Initiation :
    12/18/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    Olaparib in Metastatic Breast Cancer (TBCRC 048) (NCT03344965)
    Phase 2
    Beth Israel Deaconess Medical Center
    Active, not recruiting
    Last update posted :
    10/11/2024
    Initiation :
    04/01/2018
    Primary completion :
    07/30/2025
    Completion :
    12/30/2025
    PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    HR positive • PALB2 mutation • PGR positive • BRCA mutation
    |
    Lynparza (olaparib)
    Niraparib As First Line Therapy with Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC) (NCT05442749)
    Phase 2
    Centre Leon Berard
    Withdrawn
    Last update posted :
    09/11/2024
    Initiation :
    10/28/2022
    Primary completion :
    01/15/2026
    Completion :
    09/15/2026
    BRCA1 • BRCA2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • FANCD2
    |
    Zejula (niraparib)
    Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (NCT03047135)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    05/24/2023
    Completion :
    05/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Lynparza (olaparib)
    Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load (NCT04336943)
    Phase 2
    University of Washington
    Active, not recruiting
    Last update posted :
    07/02/2024
    Initiation :
    04/13/2021
    Primary completion :
    06/20/2024
    Completion :
    06/06/2025
    BRCA2 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • CD4 • RAD51D • NBN • ABRAXAS1 • GEN1
    |
    MSI-H/dMMR • HRD
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study (NCT05287451)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/10/2022
    Primary completion :
    12/26/2026
    Completion :
    12/26/2026
    BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D
    |
    BRCA2 mutation • BRCA1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation
    Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations (NCT02760849)
    Phase N/A
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    05/02/2016
    Primary completion :
    05/31/2041
    Completion :
    05/31/2041
    BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
    |
    BARD1 mutation
    Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial (NCT04693468)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    12/01/2020
    Primary completion :
    09/03/2025
    Completion :
    09/03/2025
    ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D
    |
    MET amplification • MET mutation • MET expression • ALK translocation
    |
    Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • Inlyta (axitinib)
    Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (D5330C00004) (NCT02264678)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    10/31/2014
    Primary completion :
    08/05/2026
    Completion :
    08/05/2026
    HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D
    |
    HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • ceralasertib (AZD6738) • saruparib (AZD5305)
    Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (NCI10217) (NCT03842228)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/21/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN
    |
    PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)
    Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (NCT05033756)
    Phase 2
    Institut fuer Frauengesundheit
    Active, not recruiting
    Last update posted :
    05/07/2024
    Initiation :
    07/30/2022
    Primary completion :
    01/01/2025
    Completion :
    02/01/2026
    HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4
    |
    HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations (NCT05807126)
    Phase 1
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    05/02/2024
    Initiation :
    03/05/2024
    Primary completion :
    12/06/2026
    Completion :
    12/06/2026
    IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3
    |
    HR positive • BRCA mutation • CD47 expression
    |
    Lynparza (olaparib) • magrolimab (ONO-7913)
    A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) (NCT05338346)
    Phase 1
    Antengene Discovery Limited
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    07/08/2022
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    TP53 mutation • FANCF mutation
    |
    ATG-018
    TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention (TUBA-WISP II) (NCT04294927)
    Phase N/A
    University Medical Center Nijmegen
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    03/01/2020
    Primary completion :
    02/17/2040
    Completion :
    02/17/2040
    BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D
    |
    BRIP1 mutation • RAD51 mutation
    A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer (BrUOG 360) (NCT04253262)
    Phase 1/2
    Brown University
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    04/03/2020
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRIP1 mutation
    |
    Rubraca (rucaparib) • Aliqopa (copanlisib)
    I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) (NCT05986071)
    Phase 1/2
    Institut Paoli-Calmettes
    Not yet recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/01/2024
    Primary completion :
    04/01/2027
    Completion :
    10/15/2027
    HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1
    |
    HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation
    |
    fulvestrant • tuvusertib (M1774)
    Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) (NCT04779151)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/07/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2027
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD
    |
    HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) (NCT04276376)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/12/2019
    Primary completion :
    12/01/2024
    Completion :
    04/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial (NCT05967286)
    Phase 2
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    03/20/2024
    Initiation :
    10/23/2023
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    HER-2 • ER • PIK3CA • BRCA1 • BRCA2 • BAP1 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    ER positive • HER-2 negative • PIK3CA mutation • ER negative
    |
    Lynparza (olaparib) • Piqray (alpelisib)
    Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/26/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation
    |
    Talzenna (talazoparib)
    Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) (NCT03786796)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/05/2024
    Initiation :
    06/03/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives (NCT04257045)
    Phase N/A
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/14/2024
    Initiation :
    08/21/2019
    Primary completion :
    04/30/2024
    Completion :
    04/30/2024
    TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • EPCAM • BARD1 • DICER1